Andrew S. Davis - 20 May 2021 Form 4 Insider Report for Silk Road Medical Inc

Role: Chief Commercial Officer
Signature: /s/Mhairi Jones, by power of attorney
Issuer symbol: N/A
Transactions as of: 20 May 2021
Net transactions value: -$256,974
Form type: 4
Filing time: 02 Jun 2021, 21:26:12 UTC
Next filing: 06 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SILK	Common Stock	Options Exercise	$2,651	+1,657	+5.3%	$1.60^*	32,897	01 Jun 2021	Direct	F1
transaction	SILK	Common Stock	Sale	$78,254	-1,657	-5%	$47.23	31,240	01 Jun 2021	Direct	F1, F2
transaction	SILK	Common Stock	Options Exercise	$22,075	+4,667	+15%	$4.73	35,907	01 Jun 2021	Direct	F1
transaction	SILK	Common Stock	Sale	$220,406	-4,667	-13%	$47.23	31,240	01 Jun 2021	Direct	F1, F2
transaction	SILK	Common Stock	Award	$16,960	+420	+1.3%	$40.38	31,660	20 May 2021	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SILK	Option (right to buy)	Options Exercise	$0	-1,657	-5%	$0.000000	31,475	01 Jun 2021	Common Stock	1,657	$1.60	Direct	F1, F4
transaction	SILK	Option (right to buy)	Options Exercise	$0	-4,667	-5.5%	$0.000000	79,592	01 Jun 2021	Common Stock	4,667	$4.73	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.
F2	This transaction was executed in multiple trades at price ranging from $46.67 to $48.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3	These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c).
F4	All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F5	One forty-eighth of the shares subject to the option shall vest on September 1, 2017 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.